Dihydropyridines in Critical Care: How CRRT Changes the Game for Blood Pressure Medications
Ask most cardiologists what they know about amlodipine and they’ll tell you it is one of the cleanest, most forgiving blood pressure drugs in the formulary. Long half-life, gradual onset, high protein binding that keeps it where it needs to be. Easy to dose, easy to live with. It’s on the WHO’s essential medicines list for a reason.
Now ask those same cardiologists what happens to amlodipine when the patient is on a continuous renal replacement circuit, and you will mostly get a shrug. That is not a knock on cardiologists. It is a knock on the entire system of drug development and clinical research, which for decades treated ICU pharmacokinetics as an afterthought.
Dihydropyridines as a class matter enormously in cardiovascular medicine. Amlodipine, nifedipine, felodipine, nicardipine. They block L-type calcium channels in vascular smooth muscle, letting blood vessels relax and dilate. The result is lower systemic vascular resistance and less cardiac workload. Cardiologists reach for them in hypertension, angina, hypertrophic cardiomyopathy, even Raynaud’s phenomenon. Nephrologists sometimes prefer them over ACE inhibitors in kidney disease patients because they do not further compromise renal perfusion. They are, in short, everywhere.
Which makes what a research team at the University of Utah found both surprising and a little unsettling.
The Study Setup
The researchers were interested in a problem that does not get enough attention in critical care: drug loss during CRRT. Continuous Renal Replacement Therapy is the go-to kidney support modality for hemodynamically unstable ICU patients, especially children. Unlike conventional dialysis which runs in sessions, CRRT hums along continuously, clearing solutes and fluid at a slower, gentler pace that better approximates natural kidney function.
The problem is that gentle does not mean selective. The CRRT circuit’s filters and tubing expose blood to large surface areas of synthetic material. Drugs in that blood can do one of two things: stick to those surfaces (adsorption) or pass through the semi-permeable membrane into the dialysis fluid (membrane clearance). Sometimes both. The degree depends on the drug’s molecular size, lipophilicity, protein binding, and a dozen other variables that are difficult to predict without actually measuring them.
So the researchers built a closed-circuit simulation of pediatric CRRT and ran five drugs through it individually, then together. The drugs were amlodipine, fentanyl, fluconazole, methylprednisolone, and midazolam. They measured how much of each came out the other end after six hours.
The Results Were Not Reassuring
When drugs were tested alone in the circuit, recovery rates told a troubling story.
Fluconazole was almost entirely gone. 0.4% recovery after six hours. Methylprednisolone came in at 11.4%. Fentanyl landed at 22%. Amlodipine, the drug that matters most for this discussion, came in at 49%. That means in a single-drug scenario, a pediatric patient on CRRT receiving a standard amlodipine dose would be absorbing less than half of it. The rest was adhering to circuit tubing and filters, never reaching systemic circulation.
Compare that to the control circuits, which had no CRRT filter attached. Those showed 90 to 113% recovery, which is essentially what you would expect from normal pharmacokinetics.
The clinical implication is uncomfortable to sit with. You are giving a very sick child a blood pressure medication. You think you are giving a therapeutic dose. Half of it is disappearing into a plastic tube before it ever reaches the bloodstream. And you may not know this is happening, because therapeutic drug monitoring is not routine for amlodipine in most ICUs.
Then It Got Stranger
When the researchers ran all five drugs simultaneously through the same circuit, something unexpected happened. Amlodipine recovery jumped from 49% to 109%. Fluconazole went from 0.4% to 2.46%. Fentanyl barely budged, but the others all improved.
The most plausible explanation is competition for adsorption sites. When five drugs are fighting over the same sticky surfaces in the circuit, they share the losses. No single drug monopolizes the available binding capacity. This is the drug-drug-circuit interaction that the research team flagged as needing urgent follow-up.
It also means that single-drug CRRT pharmacokinetic studies may be misleading, because ICU patients are almost never on just one medication. They are on five, ten, sometimes twenty drugs simultaneously. Each one warps the circuit’s behavior toward the others. The net effect on any individual drug’s bioavailability becomes essentially unpredictable from first principles alone.
Why Amlodipine Specifically
Amlodipine is worth dwelling on because it is so widely used and because its physicochemical properties make it a useful case study. It is roughly 93 to 98% protein-bound. It is lipophilic. These traits normally make a drug more stable in plasma and less likely to be cleared by the kidneys. In a CRRT circuit, though, the lipophilicity that keeps it stable in the bloodstream may actually drive it toward circuit surfaces, since those surfaces are also non-polar and hydrophobic.
This is not a drug design flaw. It is a context change that nobody anticipated when the dosing regimens were established. The same molecule behaving differently not because of the disease but because of the medical technology keeping the patient alive.
For patients on chronic amlodipine therapy who are admitted to the ICU and placed on CRRT, there is currently no reliable guidance on whether to increase the dose, decrease it, or leave it unchanged. That is a gap in clinical knowledge that needs filling, especially in pediatrics, where the window for safe experimentation is narrow.
The Pediatric Angle Makes This Worse
The study modeled a 10-kilogram child, which is the kind of patient who typically fills a pediatric ICU bed when acute kidney injury strikes. Pediatric CRRT patients face mortality rates between 30% and 70%, a range so grim it should concentrate everyone’s attention. It is impossible to say what proportion of those deaths is attributable to inadequate drug dosing, but it is equally impossible to rule it out.
A critically ill child on CRRT may be receiving vasopressors, antibiotics, antifungals, sedatives, analgesics, and antihypertensives all at once. Every single one of those drugs interacts with the circuit in ways that are, at best, poorly quantified. The compounding uncertainty is enormous.
The researchers are pushing toward physiology-based pharmacokinetic modeling that could eventually give clinicians real-time dose adjustment recommendations based on the specific CRRT configuration in use, the patient’s weight, and the cocktail of concurrent medications. That is the right direction. But it will take years of coordinated multi-center work to build models robust enough for clinical deployment.
What This Tells Us About Dihydropyridines Broadly
The amlodipine story is ultimately a story about the limits of pharmacokinetic knowledge in extreme clinical environments. Dihydropyridines as a drug class are not in trouble. Amlodipine remains a solid choice for hypertension management in most settings. The issue is not the drug. The issue is the context.
In an ICU, where organ function is compromised, multiple drugs are running simultaneously, and kidney support machines are actively processing the bloodstream, the rules change. Absorption, distribution, metabolism, and excretion all behave differently than they do in the textbook studies that established dosing guidelines. For drugs like amlodipine that were never tested in CRRT patients, we are essentially practicing with educated guesses.
This should motivate more research, not less. The population of ICU patients requiring CRRT is growing as critical care medicine advances and more complex patients survive long enough to need organ support. The number of people exposed to these drug-circuit interactions will only increase.
Practical Takeaways for Clinicians
Until better data emerges, what should a bedside clinician do? A few things seem reasonable. Be aware that amlodipine and other dihydropyridines may have reduced bioavailability in CRRT patients. If therapeutic drug monitoring is available for a given drug, use it aggressively in this population. Document baseline blood pressure responses and adjust empirically if the clinical picture is not matching expectations. And flag this uncertainty in handoffs, because it is easy for the next shift to assume standard dosing applies when it may not.
The machines keep patients alive. They also create pharmacology problems that we have only started to map.
FAQ
What are dihydropyridines?
Dihydropyridines are a group of calcium channel blockers used mainly to treat high blood pressure and angina. Amlodipine, nifedipine, and felodipine are the most common ones. They work by blocking calcium channels in blood vessel walls, allowing vessels to relax and lowering blood pressure.
What is CRRT?
CRRT stands for Continuous Renal Replacement Therapy. It is a form of dialysis used in intensive care units for patients with severe kidney failure who are too unstable for conventional dialysis. The machine runs continuously, filtering the blood at a slow, steady pace.
How much amlodipine is lost in a CRRT circuit?
In laboratory simulations, only about 49% of amlodipine was recovered after six hours when the drug was run through the circuit alone. Nearly half the dose was lost to adsorption onto circuit tubing and filters.
Why does amlodipine recovery improve when other drugs are present?
Researchers believe multiple drugs compete for the same adsorption sites on circuit surfaces. When several drugs are circulating together, each one takes only a portion of the available binding capacity, so individual drug losses decrease.
Does this apply to adults or just children?
The laboratory simulation modeled pediatric CRRT conditions. However, the underlying physics and chemistry of drug-circuit interactions apply to adult patients too. Different CRRT machines and settings will produce different numbers, but the core problem is the same.
Should doctors stop using dihydropyridines in CRRT patients?
No. These drugs are valuable antihypertensives and there is often no better alternative for managing blood pressure in ICU patients. The answer is not avoidance but awareness. Dosing may need adjustment, and close monitoring of blood pressure response is advisable.
What needs to happen next in research?
Multi-center studies testing different CRRT configurations and drug combinations in both pediatric and adult populations. The goal is to build physiology-based pharmacokinetic models that can give clinicians practical dose adjustment guidance for real patients, not just laboratory simulations.
